Ultragenyx Pharmaceutical Inc. Agrees to Sell Fayuvi Voucher for $203 Million

Ultragenyx Pharmaceutical Inc. agreed to sell a U.S. Food and Drug Administration (FDA) priority review voucher for $203 million. The voucher was received in connection with the September approval of Fayuvi, a rare disease gene therapy also known as rebisufligene etisparvovec. John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.